RespireRx Pharmaceuticals Inc (RSPI)

[gfp927z]

Nice going - >>> RespireRx Pharmaceuticals Inc. Retracts Efficacy Data in September 12, 2016 Press Release Announcing Preliminary Top-Line Analysis of Safety and Efficacy Data From Duke University Phase 2A Clinicial Trial of CX 1739


October 04, 2016



http://finance.yahoo.com/news/respirerx-pharmaceuticals-inc-retracts-efficacy-123000041.html



GLEN ROCK, NJ--(Marketwired - Oct 4, 2016) - On September 12, 2016, RespireRx Pharamceuticals Inc. ( OTCQB : RSPI ) ( OTCQB : RSPID ) ("RespireRx" or the "Company") issued a press release announcing preliminary top-line analysis of safety and efficacy data from a Phase 2A clinical trial of the Company's proprietary ampakine compound, CX1739, that was recently conducted at Duke University.

On October 3, 2016, the Company discovered an error in the data reported to it that the Company believes will effect the efficacy data analysis. However, at this time, the Company does not know the extent of the effect. The safety data is expected to remain unchanged. Accordingly, the Company hereby retracts the efficacy data contained in the September 12, 2016 press release.

The Company is in the process of re-analyzing the data and expects to report the results in a final report by the end of 2016.

Additional information about the Company and the matters discussed herein can be obtained on the Company's web-site at www.RespireRx.com or in the Company's filings with the U.S. Securities and Exchange Commission at www.sec.gov.

<<<